Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-α transcriptional activity

Endocrinology

Volumn 150, Issue 4, 2009, Pages 1588-1596

  Karmakar, Sudipan ^a   Foster, Estrella A ^a   Smith, Carolyn L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR ALPHA; NUCLEAR RECEPTOR COACTIVATOR 2; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P160; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPLETION;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGEN RECEPTOR ALPHA; FLOW CYTOMETRY; HISTONE ACETYLTRANSFERASES; HUMANS; NUCLEAR RECEPTOR COACTIVATOR 2; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 64049119546     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-1001     Document Type: Article

References (45)

1. Henderson BE, Ross RK, Bernstein L 1988 Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 48:246-253
2. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson J-Å 2001 Mechanisms of estrogen action. Physiol Rev 81:1535-1565
3. McKenna NJ, Lanz RB, O'Malley BW 1999 Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20:321-344
4. 1S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 272:10882-10894
5. Dubik D, Shiu RP 1992 Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7:1587-1594
6. Hodges LC, Cook JD, Lobenhofer EK, Li L, Bennett L, Bushel PR, Aldaz CM, Afshari CA, Walker CL 2003 Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res 1:300 -311
7. Vos CB, Ter Haar NT, Peterse JL, Cornelisse CJ, vande Vijver MJ 1999 Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J Pathol 187:279-284
8. Teixeira C, Reed JC, Pratt MA 1995 Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55:3902-3907
9. Song RX-D, Santen RJ 2003 Apoptotic action of estrogen. Apoptosis 8:55-60
10. Kumar A, Vadlamudi RK, Adam L 2000 Apoptosis in mammary gland and cancer. Endocr Relat Cancer 7:257-269
11. Smith CL, O'Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45-71
12. Xu J, Li Q 2003 Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 17:1681-1692
13. Labhart P, Karmakar S, Salicru EM, Egan BS, Alexiadis V, O'Malley BW, Smith CL 2005 Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator. Proc Natl Acad Sci USA 102:1339 -1344
14. Li X, Wong J, Tsai SY, Tsai M-J, O'Malley BW 2003 Progesterone and glu- cocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol Cell Biol 23:3763-3773
15. Rogatsky I, Luecke HF, Leitman DC, Yamamoto KR 2002 Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. Proc Natl Acad Sci USA 99:1670116706
16. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyli S, Fox MS, Leitman DC 2006 Distinct roles of unliganded estrogen receptors in transcriptional repression. Mol Cell 21:555-564
17. Tai H, Kubota M, Kato S 2000 Involvement of nuclear receptor coactivator SRC-1 in estrogen-dependent cell growth of MCF-7 cells. Biochem Biophys Res Commun 267:311-316
18. Cavarretta ITR, Mukopadhyay R, Lonard DM, Cowsert LM, Bennett CF, O'Malley BW, Smith CL 2002 Reduction of coactivator expression by anti- sense oligodeoxynucleotides inhibits ERa transcriptional activity and MCF-7 proliferation. Mol Endocrinol 16:253-270
19. List H-J, Lauritsen KJ, Reiter R, Powers C, Wellstein A, Riegel AT 2001 Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J Biol Chem 276:23763-23768
20. LouieMC, ZouJX, Rabinovich A, ChenH-W2004 ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol 24:5157-5171
21. Weldon CB, Elliott S, Zhu Y, Clayton JL, Curiel TJ, Jaffe BM, Burow ME 2004 Regulation of estrogen-mediated cell survival and proliferation by p160 co- activators. Surgery 136:346 -354
22. Shang Y, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468
23. Lonard DM, Tsai SY, O'Malley BW 2004 Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins. Mol Cell Biol 24:14 -24
24. Peterson TJ, Karmakar S, Pace MC, Gao T, Smith CL 2007 The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor-a transcriptional activity. Mol Cell Biol 27:5933-5948
25. Lonard DM, Nawaz Z, Smith CL, O'Malley BW 2000 The 26S proteasome is required for estrogen receptor-α and coactivator turn-over and for efficient estrogen receptor-α transactivation. Mol Cell 5:939 -948
26. Shao W, Keeton EK, McDonnell DP, Brown M 2004 Coactivator AIBI links estrogen receptor transcriptional activityand stability. Proc Natl Acad Sci USA 101:11599 -11604
27. Clarke R, Brunner N, Katzenellenbogen BS, Thompson EW, Norman MJ, Koppi C, PaikS, LippmanME, DicksonRB 1989 Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci USA 86:3649-3653
28. Lilling G, Hacohen H, Nordenberg J, Livnat T, Rotter V, Sidi Y 2000 Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: possible relation to high bcl-2/bax ratio? Cancer Lett 161:27-34
29. Louie MC, Revenko AS, Zou JX, Yao J, Chen H-W2006 Direct control of cell cycle gene expression by proto-oncogene product ACTR, and its autoregulation underlies its transforming activity. Mol Cell Biol 26:3810 -3823
30. Zhou G, Hashimoto Y, Kwak I, Tsai SY, Tsai M-J 2003 Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol 23:7742-7755
31. Vivanco I, Sawyers CL 2002 The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489 -501
32. Zou JX, Zhong Z, Shi XB, Tepper CG, DeVere White RW, Kung HJ, Chen H 2006 ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes. Prostate 66:1474 -1486
33. Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WEI, Erdem H, Frolov A, Smith CL, Ayala GE, Ittmann MM, Weigel NL 2006 Androgens modulate expression of transcription intermediary factor 2, an androgen receptor co- activator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 66:10594-10602
34. Kandouz M, Lombet A, Perrot J-Y, Jacob D, Carvajal S, Kazem A, Rostene W, Therwath A, Gompel A 1999 Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. J Steroid Biochem Mol Biol 69:463-471
35. Perillo B, Sasso A, Abbondanza C, Palumbo G 2000 17β-Estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20:2890-2901
36. Yu C, York B, Wang S, Feng Q, XuJ, O'Malley BW2007 An essential function of the SRC-3 coactivator in suppression of cytokine mRNA translation and inflammatory response. Mol Cell 25:765-778
37. Klinge CM, Jernigan SC, Mattingly KA, Risinger KE, Zhang J 2004 Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors α and β by coactivators and corepressors. J Mol Endocrinol 33:387-410
38. Planas-Silva MD, Weinberg RA 1997 Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 17:4059 -4069
39. Zhang H, Yi X, Sun X, Yin N, Shi B, Wu H, Wang D, Wu G, Shang Y 2004 Differential gene regulation by the SRC family of coactivators. Genes Dev 18:1753-1765
40. Wood JR, Likhite VS, Loven MA, Nardulli AM 2001 Allosteric modulation of estrogen receptor conformation by different estrogen response elements. Mol Endocrinol 15:1114-1126
41. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, Wong J, Allred DC, Clark GM, Schiff R 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361
42. Dihge L, Bendahl PO, Grabau D, Isola J, Lovgren K, Ryden L, Ferno M 2008 Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat 109:255-262
43. Myers E, Fleming FJ, Crotty TB, Kelly G, McDermott EW, O'Higgins NJ, Hill AD, Young LS 2004 Inverse relationship between ER-β and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br J Cancer 91:1687-1693
44. Morrison AJ, Herrick RE, Heinsohn EC, Schiff R, Osborne CK 2003 Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. Mol Endocrinol 17:1543-1554
45. Sarvilinna N, Eronen H, Miettinen S, Vienonen A, Ylikomi T 2006 Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells. Int J Cancer 118:832-840